Proxima (formerly VantAI) is building a platform that maps protein-protein interactions across the proteome and designs small-molecule drugs that modulate those interactions. Its NeoLink structural-proteomics system generates large-scale complex data, while the companion Neo AI model suite applies frontier machine-learning techniques to identify and design molecular glues, PROTACs, and other proximity-modulating compounds. The company focuses on expanding the druggable target space in oncology, immunology, and additional disease areas, aiming to improve safety and shorten development timelines for historically “undruggable” targets. Proxima has already secured multibillion-dollar research collaborations with Johnson & Johnson, Bristol Myers Squibb, and Blueprint Medicines (now part of Sanofi), with the first co-developed program expected to enter clinical trials in 2026. It maintains both an internal pipeline and extensive external partnerships to advance novel proximity therapeutics. Financially, the firm closed an oversubscribed $80 million seed round and benefits from the non-dilutive value of its large pharmaceutical collaborations. Headquartered in New York and Boston, Proxima is positioning its technology and data layer as foundational infrastructure for the next generation of AI-driven drug discovery.

Total raised

$80M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2026